Diurnal alterations in circadian genes and peptides in major depressive disorder before and after escitalopram treatment

Psychoneuroendocrinology

Volumn 38, Issue 11, 2013, Pages 2789-2799

  Li, Su Xia ^a   Liu, Li Jing ^a   Xu, Ling Zhi ^a   Gao, Lei ^b   Wang, Xin Fu ^c   Zhang, Jing Tao ^d   Lu, Lin ^a  

^a PEKING UNIVERSITY   (China)

^b Psychiatric Hospital (Jining)   (China)

^c Hebei Province Rong Jun Hospital   (China)

^d Beijing Daxing Hospital   (China)

Author keywords

Circadian rhythms; Clock genes; Escitalopram; Hormones; Major depressive disorder; Peptides

Indexed keywords

CORTICOTROPIN; CRYPTOCHROME 1; ESCITALOPRAM; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROCORTISONE; MELATONIN; MESSENGER RNA; PER1 PROTEIN; PER2 PROTEIN; PROTEIN BMAL1; SOMATOMEDIN C; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BMAL1 GENE; CHRONOMETRIC PARAMETERS; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CRY1 GENE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; GENE; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; GSK 3BETA GENE; HORMONE BLOOD LEVEL; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MALE; NPAS2 GENE; OUTCOME ASSESSMENT; PERIOD1 GENE; PERIOD2 GENE; PERIOD3 GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE;

CIRCADIAN RHYTHMS; CLOCK GENES; ESCITALOPRAM; HORMONES; MAJOR DEPRESSIVE DISORDER; PEPTIDES;

ADRENOCORTICOTROPIC HORMONE; ADULT; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; CIRCADIAN RHYTHM SIGNALING PEPTIDES AND PROTEINS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; GENE EXPRESSION; GROWTH HORMONE; HUMANS; HYDROCORTISONE; INSULIN-LIKE GROWTH FACTOR I; MALE; MELATONIN; NEUROPEPTIDES; SYMPTOM ASSESSMENT; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84886100733     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2013.07.009     Document Type: Article

References (47)

1. Aberg D. Role of the growth hormone/insulin-like growth factor 1 axis in neurogenesis. Endocr. Dev. 2010, 17:63-76.
2. Aberg N.D., Brywe K.G., Isgaard J. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. Sci. World J. 2006, 6:53-80.
3. American Psychiatric Association DSM-IV: Diagnostic and Statistical Manual of Mental Disorders 1994, Am. Psychiatric Assoc. Press, Washington, DC.
4. Aton S.J., Colwell C.S., Harmar A.J., Waschek J., Herzog E.D. Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nat. Neurosci. 2005, 8:476-483.
5. Azorin J.M., Llorca P.M., Despiegel N., Verpillat P. Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder. Encephale 2004, 30:158-166.
6. Benedetti F., Serretti A., Colombo C., Lorenzi C., Tubazio V., Smeraldi E. A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci. Lett. 2004, 368:123-126.
7. Bhattacharjee Y. Psychiatric research. Is internal timing key to mental health?. Science 2007, 317:1488-1490. (New York, NY).
8. Bob P., Fedor-Freybergh P. Melatonin, consciousness, and traumatic stress. J. Pineal Res. 2008, 44:341-347.
9. Burke H.M., Davis M.C., Otte C., Mohr D.C. Depression and cortisol responses to psychological stress: a meta-analysis. Psychoneuroendocrinology 2005, 30:846-856.
10. Carro E., Nunez A., Busiguina S., Torres-Aleman I. Circulating insulin-like growth factor I mediates effects of exercise on the brain. J. Neurosci. 2000, 20:2926-2933.
11. Chang F.Y., Doong M.L., Chen T.S., Lee S.D., Wang P.S. Vasoactive intestinal polypeptide appears to be one of the mediators in misoprostol-enhanced small intestinal transit in rats. J. Gastroenterol. Hepatol. 2000, 15:1120-1124.
12. Cizza G., Marques A.H., Eskandari F., Christie I.C., Torvik S., Silverman M.N., Phillips T.M., Sternberg E.M. Elevated neuroimmune biomarkers in sweat patches and plasma of premenopausal women with major depressive disorder in remission: the POWER study. Biol. Psychiatry 2008, 64:907-911.
13. Crasson M., Kjiri S., Colin A., Kjiri K., L'Hermite-Baleriaux M., Ansseau M., Legros J.J. Serum melatonin and urinary 6-sulfatoxymelatonin in major depression. Psychoneuroendocrinology 2004, 29:1-12.
14. Deuschle M., Blum W.F., Strasburger C.J., Schweiger U., Weber B., Korner A., Standhardt H., Gotthardt U., Schmider J., Pflaum C.D., Heuser I. Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology 1997, 22:493-503.
15. Dumont G.J., de Visser S.J., Cohen A.F., van Gerven J.M. Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. Br. J. Clin. Pharmacol. 2005, 59:495-510.
16. Ehlen J.C., Grossman G.H., Glass J.D. In vivo resetting of the hamster circadian clock by 5-HT7 receptors in the suprachiasmatic nucleus. J. Neurosci. 2001, 21:5351-5357.
17. Flood J.F., Garland J.S., Morley J.E. Vasoactive intestinal peptide (VIP): an amnestic neuropeptide. Peptides 1990, 11:933-938.
18. Germain A., Kupfer D.J. Circadian rhythm disturbances in depression. Hum. Psychopharmacol. 2008, 23:571-585.
19. Gouin J.P., Connors J., Kiecolt-Glaser J.K., Glaser R., Malarkey W.B., Atkinson C., Beversdorf D., Quan N. Altered expression of circadian rhythm genes among individuals with a history of depression. J. Affect. Disord. 2010, 126:161-166.
20. Gould T.D., Manji H.K. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005, 30:1223-1237.
21. Hamilton F.M. Hamilton anxiety scale. ECDEU Assessment Manual for Psychopharmacology 1976, 193-198. U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD. W. Guy (Ed.).
22. Hickie I.B., Rogers N.L. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011, 378:621-631.
23. Jarrett D.B., Miewald J.M., Kupfer D.J. Recurrent depression is associated with a persistent reduction in sleep-related growth hormone secretion. Arch. Gen. Psychiatry 1990, 47:113-118.
24. Juruena M.F., Cleare A.J., Papadopoulos A.S., Poon L., Lightman S., Pariante C.M. Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl.) 2006, 189:225-235.
25. Kazanis I., Giannakopoulou M., Philippidis H., Stylianopoulou F. Alterations in IGF-I. BDNF and NT-3 levels following experimental brain trauma and the effect of IGF-I administration. Exp. Neurol. 2004, 186:221-234.
26. Kusanagi H., Hida A., Satoh K., Echizenya M., Shimizu T., Pendergast J.S., Yamazaki S., Mishima K. Expression profiles of 10 circadian clock genes in human peripheral blood mononuclear cells. Neurosci. Res. 2008, 61:233-240.
27. Li S.X., Liu L.J., Jiang W.G., Lu L. Morphine withdrawal produces circadian rhythm alterations of clock genes in mesolimbic brain areas and peripheral blood mononuclear cells in rats. J. Neurochem. 2009, 109:1668-1679.
28. Li S.X., Liu L.J., Jiang W.G., Sun L.L., Zhou S.J., Le Foll B., Zhang X.Y., Kosten T.R., Lu L. Circadian alteration in neurobiology during protracted opiate withdrawal in rats. J. Neurochem. 2010, 115:353-362.
29. Li S.X., Shi J., Epstein D.H., Wang X.I., Zhang X.L., Bao Y.P., Zhang D., Zhang X.Y., Kosten T.R., Lu L. Circadian alteration in neurobiology during 30 days of abstinence in heroin users. Biol. Psychiatry 2009, 65:905-912.
30. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757.
31. McCusker R.H., McCrea K., Zunich S., Dantzer R., Broussard S.R., Johnson R.W., Kelley K.W. Insulin-like growth factor-I enhances the biological activity of brain-derived neurotrophic factor on cerebrocortical neurons. J. Neuroimmunol. 2006, 179:186-190.
32. Mendlewicz J., Linkowski P., Kerkhofs M., Desmedt D., Golstein J., Copinschi G., Van Cauter E. Diurnal hypersecretion of growth hormone in depression. J. Clin. Endocrinol. Metab. 1985, 60:505-512.
33. Mojon A., Fernandez J.R., Hermida R.C. Chronolab: an interactive software package for chronobiologic time series analysis written for the Macintosh computer. Chronobiol. Int. 1992, 9:403-412.
34. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
35. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997, 349:1498-1504.
36. Otte C., Hart S., Neylan T.C., Marmar C.R., Yaffe K., Mohr D.C. A meta-analysis of cortisol response to challenge in human aging: importance of gender. Psychoneuroendocrinology 2005, 30:80-91.
37. Pacchierotti C., Iapichino S., Bossini L., Pieraccini F., Castrogiovanni P. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front. Neuroendocrinol. 2001, 22:18-32.
38. Paslakis G., Blum W.F., Deuschle M. Intranasal insulin-like growth factor I (IGF-I) as a plausible future treatment of depression. Med. Hypotheses 2012, 79:222-225.
39. Peteranderl C., Antonijevic I.A., Steiger A., Murck H., Held K., Frieboes R.M., Schaaf L. Nocturnal secretion of TSH and ACTH in male patients with depression and healthy controls. J. Psychiatr. Res. 2002, 36:189-196.
40. Posener J.A., DeBattista C., Williams G.H., Chmura Kraemer H., Kalehzan B.M., Schatzberg A.F. 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch. Gen. Psychiatry 2000, 57:755-760.
41. Rubin R.T., Poland R.E., Lesser I.M. Neuroendocrine aspects of primary endogenous depression. X. Serum growth hormone measures in patients and matched control subjects. Biol. Psychiatry 1990, 27:1065-1082.
42. Sackeim H.A. The definition and meaning of treatment-resistant depression. J. Clin. Psychiatry 2001, 62:10-17.
43. Sjoholm L.K., Backlund L., Cheteh E.H., Ek I.R., Frisen L., Schalling M., Osby U., Lavebratt C., Nikamo P. CRY2 is associated with rapid cycling in bipolar disorder patients. PLoS ONE 2010, 5:e12632.
44. Takashima A., Maeda Y., Itoh S. Vasoactive intestinal peptide (VIP) causes memory impairment in passive avoidance responding of the rat. Peptides 1993, 14:1067-1071.
45. Voderholzer U., Laakmann G., Wittmann R., Daffner-Bujia C., Hinz A., Haag C., Baghai T. Profiles of spontaneous 24-hour and stimulated growth hormone secretion in male patients with endogenous depression. Psychiatry Res. 1993, 47:215-227.
46. Weber-Hamann B., Blum W.F., Kratzsch J., Gilles M., Heuser I., Deuschle M. Insulin-like growth factor-I (IGF-I) serum concentrations in depressed patients: relationship to saliva cortisol and changes during antidepressant treatment. Pharmacopsychiatry 2009, 42:23-28.
47. Wei Y.M., Li S.X., Shi H.S., Ding Z.B., Luo Y.X., Xue Y.X., Lu L., Yu C.X. Protracted cocaine withdrawal produces circadian rhythmic alterations of phosphorylated GSK-3beta in reward-related brain areas in rats. Behav. Brain Res. 2011, 218:228-233.